Race Oncology Management

Management criteria checks 3/4

Race Oncology's CEO is Daniel Tillett, appointed in Nov 2023, has a tenure of less than a year. total yearly compensation is A$835.75K, comprised of 39.8% salary and 60.2% bonuses, including company stock and options. directly owns 9.58% of the company’s shares, worth A$30.20M. The average tenure of the management team and the board of directors is 1 years and 3.4 years respectively.

Key information

Daniel Tillett

Chief executive officer

AU$835.7k

Total compensation

CEO salary percentage39.8%
CEO tenureless than a year
CEO ownership9.6%
Management average tenureless than a year
Board average tenure3.4yrs

Recent management updates

Recent updates

We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

May 10
We Think Race Oncology (ASX:RAC) Needs To Drive Business Growth Carefully

We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Jan 23
We're Not Very Worried About Race Oncology's (ASX:RAC) Cash Burn Rate

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 05
Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

Jun 20
Companies Like Race Oncology (ASX:RAC) Are In A Position To Invest In Growth

We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Feb 17
We're Interested To See How Race Oncology (ASX:RAC) Uses Its Cash Hoard To Grow

Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Oct 14
Here's Why We're Not At All Concerned With Race Oncology's (ASX:RAC) Cash Burn Situation

Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

Apr 01
Here's Why We're Not Too Worried About Race Oncology's (ASX:RAC) Cash Burn Situation

We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

Apr 05
We're Hopeful That Race Oncology (ASX:RAC) Will Use Its Cash Wisely

What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

Mar 01
What Percentage Of Race Oncology Limited (ASX:RAC) Shares Do Insiders Own?

How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

Jan 07
How Much Are Race Oncology Limited (ASX:RAC) Insiders Taking Off The Table?

CEO Compensation Analysis

How has Daniel Tillett's remuneration changed compared to Race Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-AU$11m

Sep 30 2023n/an/a

-AU$11m

Jun 30 2023AU$836kAU$332k

-AU$10m

Mar 31 2023n/an/a

-AU$10m

Dec 31 2022n/an/a

-AU$11m

Sep 30 2022n/an/a

-AU$11m

Jun 30 2022AU$1mAU$228k

-AU$11m

Mar 31 2022n/an/a

-AU$10m

Dec 31 2021n/an/a

-AU$9m

Sep 30 2021n/an/a

-AU$8m

Jun 30 2021AU$1mAU$167k

-AU$6m

Mar 31 2021n/an/a

-AU$5m

Dec 31 2020n/an/a

-AU$4m

Sep 30 2020n/an/a

-AU$4m

Jun 30 2020AU$147kn/a

-AU$4m

Compensation vs Market: Daniel's total compensation ($USD563.51K) is about average for companies of similar size in the Australian market ($USD640.22K).

Compensation vs Earnings: Daniel's compensation has been consistent with company performance over the past year.


CEO

Daniel Tillett

less than a year

Tenure

AU$835,747

Compensation

Dr. Daniel Tillett serves as Chief Executive Officer of Race Oncology Limited since November 22, 2023. He served as Non-Executive Director at Simble Solutions Limited since February 16, 2022 until July 03,...


Leadership Team

NamePositionTenureCompensationOwnership
Daniel Tillett
Chief Executive Officerless than a yearAU$835.75k9.58%
A$ 31.7m
Peter Smith
Executive Directorless than a yearAU$635.00no data
Brendan Brown
Chief Financial Officerless than a yearno datano data
Tim Hammond
Interim Chief Scientific Officer1.3yrsno datano data
Michelle Rashford
Chief Medical Officerless than a yearno datano data
Peter Webse
Company Secretary8.2yrsno datano data

1.0yrs

Average Tenure

Experienced Management: RAC's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Peter Smith
Executive Director1.1yrsAU$635.00no data
Martin Tallman
Member of Scientific Advisory Board7.6yrsno datano data
Phillip Lynch
Non-Executive Director4.1yrsAU$715.00k0.26%
A$ 874.4k
Douglas Smith
Member of Scientific Advisory Boardno datano datano data
Roland Walter
Member of Scientific Advisory Boardno datano datano data
Borje Andersson
Chairman of Clinical Advisory Board4.6yrsAU$815.36kno data
Jaap-Jan Boelens
Member of Clinical Advisory Board4.4yrsno datano data
Mary Harney
Independent Non-Executive Chair3.4yrsAU$148.56k0.014%
A$ 47.7k
Jianjun Chen
Member of Scientific Advisory Board3.3yrsno datano data
James Breitenbucher
Member of Scientific Advisory Board2.2yrsno datano data
Daniel Hoff
Clinical Advisory Boardno datano datano data

3.4yrs

Average Tenure

Experienced Board: RAC's board of directors are considered experienced (3.4 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.